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LETIERS TO THE EDITOR 
EFFECT OF TROGLITAZONE ON CYCLOSPORINE WHOLE BLOOD LEVELS 
Troglitazone (TGZ; Rezulin, Parke-Davis, Morris Plains, 
NJ) is a thiazolidinedione antihyperglycemic agent that has 
been shown to decrease hemoglobin A1c and decrease insulin 
requirements in patients with type 2 diabetes (1-4). It in-
creases tissue sensitivity to insulin and decreases hepatic 
glucose production but does not increase insulin secretion (5). 
At doses used clinically, troglitazone decreases plasma levels 
of ethinyl estradiol and norethindrone in oral contraceptives 
by 30%, and terfenadine by 50-70%, possibly by inducing 
hepatic metabolism by CYP3A4 (6). However, clinically sig-
nificant interactions with other drugs metabolized by 
CYP3A4, such as cyclosporine (CsA; Neoral, Novartis, East 
Hanover, New Jersey), have not been described in the liter-
ature. We report the effects of troglitazone on CsA whole 
blood levels in 11 stable renal transplant patients. 
The medical records of all renal transplant recipients re-
ceiving TGZ at our hospital were reviewed. Of 12 patients, 11 
had follow-up CsA blood levels available for analysis. All 
results are reported as mean :<:: SD. The mean age was 
54.5:<::11.6 years, and the mean time since transplantation 
was 20.5:!::: 18.2 months. All patients were receiving a stable 
CsA dose, and only one patient was receiving a drug known 
to affect the metabolism of CsA (diltiazem). The TGZ dose 
was 200-400 mg/day. The mean CsA whole blood level fell 
from 205:<::42 ng/ml at the time TGZ was initiated to 139:<::65 
ng/ml after 1 week, a decrease of 32% (P=0.0015, paired t 
test). Six patients (50%) required a CsA dosage increase of 
50-150 mg/day between 1 and 7 weeks after initiation of 
TGZ. The mean CsA dose at the time TGZ was initiated was 
358:<::93 ng/ml, compared with 392:<:: 100 ng/ml after 4 weeks 
(P=0.05, paired t test) and 404:<::92 ng/ml after 12 weeks 
(P=0.03, paired t test). There were no concomitant changes 
in medications or obvious alterations in gastrointestinal 
function that could explain the decrease in CsA blood levels. 
Despite continuous administration of diltiazem in one pa-
tient, the CsA level fell by 53% after initiation of TGZ, and 7 
weeks after initiation of TGZ, he suffered a Banff grade II 
rejection with vasculitis requiring treatment with OKT3 (Or-
thoclone OKT3, Ortho Biotech, Raritan, NJ). The serum cre-
atinine concentration increased 30% from baseline in one 
other patient and was attributed to increased CsA dosage. 
Troglitazone may be a useful antihyperglycemic agent in 
some transplant recipients with type 2 diabetes. However, it 
can lead to a reduction of CsA whole blood levels, possibly by 
inducing hepatic metabolism by CYP3A4. We have not used 
troglitazone in combination with tacrolimus to date, but we 
expect that the potential for decreased tacrolimus levels ex-
ists. Therefore, we recommend more frequent monitoring of 
either CsA or tacrolimus levels as appropriate after initiation 
of troglitazone, until a new steady state immunophilin level 
is achieved. 
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CHIMERISM AND CLONAL EXHAUSTION 
In their recent review, Bishop et al. (1) appropriately em-
phasized the essential role of donor leukocyte chimerism in 
the induction of "high-doselactivation-associated tolerance" 
(clonal exhaustion). While generously citing our discovery of 
persistent post-organ transplant chimerism (2, 3), the au-
thors attributed to us a hypothesis (i.e., "GVH-induced toler-
ance associated with chimerism" [1)) that could be construed 
as fundamentally different than theirs. 
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In actuality, the events after organ transplantation were 
explained in the cited articles "by responses of co-existing 
donor and recipient immune cells, each to the other, causing 
reciprocal clonal expansion, followed by peripheral clonal 
deletion" (2, 3). Thus, there is no inconsistency of the inter-
pretations published from the Pittsburgh and Sydney labo-
ratories except for the belief of Bishop et a1. (1) that the clonal 
exhaustion is solely of the host leukocyte population. In our 
view, a mutually exhausting double immune reaction (host 
versus graft and graft versus host) must be invoked to ex-
plain the outcome in most transplant situations (2-5). 
We also have proposed immune indifference as a second 
mechanism of organ acceptance. This is supported by the fact 
that the organ allograft is rendered progressively less immu-
nogenic by replacement of its departed migratory leukocytes 
by recipient cells of the same lineages (2-4). In addition, 
many of the donor leukocytes are ultimately disseminated to 
nonlymphoid sites where immune activation does not readily 
occur (e.g., skin and parenchymal organs) (3). Both the re-
sponse (clonal activation) or nonresponse (indifference) of the 
immune system following transplantation are governed pri-
marily by the migration and localization of the antigen (5). 
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REPLY TO "CHIMERISM AND CLONAL EXHAUSTION" 
We agree with Dr. Starzl that there is some concordance 
between our two models of transplant tolerance, although we 
maintain that there is a difference in the immune mechanism. 
In both models, donor leuk~gration to recipient tissues is 
central to the process, althoug~ our model it is not necessary 
for this to result in persistent microchimerism. Both models 
also predict that the outcome of the tolerance process will be 
deletion or inactivation of alloreactive clones of T cells. 
The major difference between the two models is in the im-
mune events which link donor cell migration with recipient 
T-cell deletion or inactivation. The Pittsburgh group uses their 
observation of persi!'tent donor-derived microchimerism in tol-
erant recipients to infer a limited graft-versus-host reaction 
~ated by "donor veto/suppressor cells, cytokine pro"E:le 
~hanges or enhancing antibodies" as the tolerance mechanism 
(1). Consequently, they have attempted to promote transplant 
acceptance by infusing donor bone marrow to increase the graft-
d.E\rsus-host reaction and subsequent microchimerism (2). 
~ur model is based on the paradoxical observation of mas-
sive upregulation of interleukin-2 and interferon-")' mRNA in 
tile recipient lymphoid tissues of tolerant arumals (3, 4). 
Parallel observations in immunological models of high-dose 
or activation-associated tolerance have led us to propose 
these as mechanisms of transplant tolerance. This leads to 
predictions different from those of the Pittsburgh model. For 
instance, we predict that increasing the amount of trans-
planted tissue and donor leukocytes promotes tolerance 
rather than rejection and that interfering with early immune 
activation by treating transplant recipients with some kinds 
of immunosuppressive drugs reduces tolerance. We have 
tested both these predictions and found that they are sup-
ported by experimental evidence (3, 5,6). We believe that def-
inition of the immune mechanism of this powerful model of 
transplant tolerance will come from examination of the early 
immune changes in recipient lymphoid tissues rather than from 
determining the nature of persistent microchimerism. 
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